The peptides marketed for weight loss are not one category. GLP-1 receptor agonists produce direct weight loss. GH-axis peptides like tesamorelin and sermorelin change body composition, mainly visceral fat, over months. Treating them as interchangeable is where most buyers go wrong.
Best peptides for weight loss is really two questions wearing one search box. GLP-1 receptor agonists and GH-axis peptides both get marketed for fat loss, but they work through unrelated mechanisms and produce very different results. Sorting them by goal, rather than by marketing volume, is the only way to pick correctly. All of these options sit under the umbrella of GH-axis peptide therapy.
- GLP-1 receptor agonists (semaglutide, tirzepatide) are the class with direct weight-loss evidence [1]
- Tesamorelin is the best-evidenced GH-axis peptide for fat, reducing visceral fat in controlled trials [2][3]
- Sermorelin and CJC-1295 with ipamorelin change body composition over months. They are not weight-loss drugs [5]
- AOD-9604 and the GH fragment 176-191 are marketed for fat loss without published human efficacy evidence
- GH-axis peptides sold through telehealth are compounded and not FDA-approved [7]
The Two Classes That Actually Matter
Every peptide sold for weight loss falls into one of two groups. The first is the GLP-1 receptor agonists, which act on appetite and gastric emptying and produce measurable weight loss on their own. The second is the GH-axis peptides, which raise growth hormone and IGF-1 and shift body composition toward less visceral fat and more lean mass over a period of months.
The distinction is not academic. A patient who wants to lose 30 pounds and a patient who wants to reduce stubborn abdominal fat while preserving muscle are looking at different drugs. Confusing the two is the most common and most expensive mistake buyers make. The slower, gentler reality of the GH-axis side is covered in peptides for weight loss, and their side effects differ by class.
GLP-1 Receptor Agonists: The Direct Weight-Loss Class
GLP-1 receptor agonists are the evidence-based option when the goal is losing weight. Semaglutide suppresses appetite and slows gastric emptying, and in the STEP 1 trial adults on once-weekly semaglutide lost roughly 15 percent of body weight over 68 weeks [1]. The class also includes tirzepatide, a dual GIP and GLP-1 receptor agonist.
These drugs are FDA-approved as brand-name products for chronic weight management, which sets them apart from every peptide compounded through telehealth. Compounded GLP-1 is a separate and less regulated supply, and it is not the approved product. The suitable candidate is someone with a genuine weight-loss target, not a body-composition adjustment.
Tesamorelin: The Best-Evidenced GH-Axis Peptide for Fat
Tesamorelin is a GHRH analog and the one GH-axis peptide with controlled trial data specific to fat. In placebo-controlled trials it reduced visceral adipose tissue in patients with excess abdominal fat [2], and pooled phase 3 data confirmed the visceral fat effect [3]. A review of GHRH-analog studies placed the visceral fat reduction at roughly 6 months of treatment [4].
Tesamorelin is FDA-approved as Egrifta for reducing excess abdominal fat in HIV-associated lipodystrophy. That is its approved use. Compounded tesamorelin prescribed through telehealth for general fat loss is off-label and is not FDA-approved. The honest framing is that it targets visceral fat specifically, not overall body weight.
Sermorelin and CJC-1295 With Ipamorelin: Body Composition, Not Weight Loss
Sermorelin is a GHRH analog that stimulates the pituitary to release its own growth hormone rather than delivering GH directly [5]. Over a 6-month protocol in patients with documented GH decline, it supports visceral fat reduction and lean mass preservation. It does not suppress appetite and does not produce GLP-1-scale weight loss.
The CJC-1295 with ipamorelin stack pairs a long-acting GHRH analog [9] with a selective secretagogue that raises GH without moving cortisol or prolactin [8]. It pushes the same GH-then-IGF-1 pathway harder, but the fat-loss logic is identical to sermorelin: indirect, gradual, and dependent on training and diet. No published trial has tested this specific combination for weight loss.
The Peptides Marketed for Fat Loss That Lack Evidence
AOD-9604 and the growth hormone fragment 176-191 are sold heavily as fat-burning peptides. Neither has published human evidence of clinically meaningful weight or fat loss. Injectable versions appear on the FDA list of bulk drug substances flagged for compounding because of significant safety concerns [6]. Marketing volume is not evidence, and here the gap is wide.
How the Classes Compare
| Peptide or class | What it does | Evidence for fat loss | Regulatory status |
|---|---|---|---|
| GLP-1 agonists (semaglutide, tirzepatide) | Suppress appetite, slow gastric emptying | Strongest; large weight-loss trials [1] | FDA-approved as brand weight-management drugs |
| Tesamorelin | GHRH analog; reduces visceral fat | Visceral fat reduction in controlled trials [2][3] | FDA-approved (Egrifta) for HIV lipodystrophy; off-label otherwise |
| Sermorelin | GHRH analog; restores GH axis | Body composition over months, not weight loss [5] | Compounded, not FDA-approved |
| CJC-1295 + ipamorelin | GHRH analog plus secretagogue | Indirect via GH/IGF-1; no combination trial [8][9] | Compounded, not FDA-approved |
| AOD-9604 / GH fragment 176-191 | Marketed as a fat-burner | No published human efficacy | Compounded; injectable flagged on FDA bulk list [6] |
Which Peptide Fits Your Goal
- You want to lose a meaningful amount of weight: GLP-1 receptor agonists have the evidence [1]
- You want to reduce visceral and abdominal fat specifically: tesamorelin has the most direct data [2][3]
- You have documented low IGF-1 and want body composition change with lean mass preserved: sermorelin or a GHRH-analog stack [5]
- You want a fast fat-burner from a peptide with no prescriber: there is no evidence-based option in that category
Bottom Line
The peptide is only half the plan. Get Thin MD pairs compounded sermorelin with a physician-supervised weight loss protocol, filled through licensed 503A pharmacies, for patients addressing GH decline and body composition together.
Frequently Asked Questions
What is the best peptide for weight loss?
There is no single best peptide, because the peptides sold for weight loss do two different things. For direct weight loss, GLP-1 receptor agonists like semaglutide have the strongest evidence, with roughly 15 percent body weight reduction over 68 weeks in the STEP 1 trial [1]. For reducing visceral fat specifically, tesamorelin, a GHRH analog, has the most direct controlled data [2][3]. Sermorelin changes body composition over months but is not a weight-loss drug [5].
Do sermorelin and GH peptides cause weight loss?
Not in the way GLP-1 drugs do. Sermorelin and other GHRH analogs raise growth hormone and IGF-1, which shifts the body toward burning visceral fat and preserving lean mass over a 6-month protocol [5]. The scale may not move much, because lean mass is preserved at the same time. Anyone expecting GLP-1-scale weight loss from a GH-axis peptide will be disappointed.
Is tesamorelin better than sermorelin for fat loss?
For fat specifically, tesamorelin has more direct evidence. It reduced visceral adipose tissue in placebo-controlled trials [2][3], and it is FDA-approved as Egrifta for excess abdominal fat in HIV-associated lipodystrophy. Sermorelin body composition effects are supported but less specific to fat [5]. Compounded tesamorelin for general fat loss is off-label and not FDA-approved.
Are peptides like AOD-9604 good for fat loss?
There is no published human evidence that AOD-9604 or the GH fragment 176-191 produce clinically meaningful fat loss. Injectable versions are on the FDA list of bulk substances flagged for significant compounding safety risks [6]. Marketing has outpaced the evidence for these peptides.
Can you stack a GH peptide with a GLP-1 drug?
Some physicians prescribe both when a patient has documented GH decline and a weight-loss target, because the two act on different systems. There is no documented pharmacokinetic interaction. Whether the combination is appropriate depends on lab data and goals and requires a prescriber experienced in both. It is not a decision to make from a vendor website.
Are weight-loss peptides FDA-approved?
It depends which one. GLP-1 drugs like semaglutide and tirzepatide are FDA-approved as brand-name products for weight management. Tesamorelin is FDA-approved as Egrifta, but only for HIV-associated lipodystrophy. Sermorelin, CJC-1295, ipamorelin, and the fat-burner peptides sold through telehealth are compounded and not FDA-approved [7].
References
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) New England Journal of Medicine, 2021. PMID: 33567185. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Metabolic effects of a growth hormone-releasing factor in patients with HIV New England Journal of Medicine, 2007. PMID: 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Effects of tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials Journal of Clinical Endocrinology & Metabolism, 2010. PMID: 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies Growth Hormone & IGF Research, 2015. PMID: 25555516. https://pubmed.ncbi.nlm.nih.gov/25555516/
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 2006. PMC2699646. https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646/
- Certain bulk drug substances for use in compounding that may present significant safety risks FDA.gov, Human Drug Compounding, 2026. FDA Category 2 bulk substances list. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Compounding and the FDA: questions and answers FDA.gov, Human Drug Compounding, 2025. Content current as of 09/16/2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- Ipamorelin, the first selective growth hormone secretagogue European Journal of Endocrinology, 1998. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
